Premium
Seroepidemiology of respiratory syncytial virus in western India with special reference to appropriate age for infant vaccination
Author(s) -
Arankalle Vidya A.,
Kulkarni Ruta,
Malshe Nandini,
Palkar Sonali,
Lalwani Sanjay,
Mishra Akhilesh Chandra
Publication year - 2019
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.25489
Subject(s) - medicine , vaccination , virus , antibody , virology , immunology , respiratory system , population , pneumovirinae , pediatrics , viral disease , paramyxoviridae , environmental health
Respiratory syncytial virus (RSV) causes significant infant mortality worldwide and a vaccine may be available soon. This study determined age‐stratified anti‐RSV antibody positivity (enzyme‐linked immunosorbent assay [ELISA]) at Pune, India (cord blood‐85 years). Antibody positivity declined from 100% at birth to 71.3% (3 months), and 0.7% (6 months). A significant rise was noted at 15 months (16%), 16 to 24 months (64.5%) and 4 years (95.2%) with concomitant IgM‐anti‐RSV positivity indicative of recent infection. Antibody decline was higher in infants born preterm than full‐term. Across subsequent age groups including the elderly, antibody positivity was similar and comparable, suggestive of repeated exposure to the virus. Early protection/vaccination is essential for the infant population.